Abstracts tagged "Gout and tophaceous gout"

Abstract Number: 3072 • 2016 ACR/ARHP Annual Meeting
Increased Platelet Reactivity in Gout: Relationship to Tophus Burden and Colchicine Use
Richard Conway¹, Claire-Louise Murphy², Anne Madigan³, Patricia Kavanagh⁴, Liz Geraghty³, Niamh Redmond⁵, Laura Helbert⁶, John J. Carey⁷, Eimear Dunne⁸, Dermot Kenny⁸ and Geraldine M. McCarthy⁹, ¹CARD Newman Research Fellow, University College Dublin, Dublin, Ireland, ²Rayne Institute, Centre for Rheumatology Research, UCL Division of Medicine, London, United Kingdom, ³Rheumatology, Mater Misericordiae University Hospital, Dublin 7, Ireland, ⁴Rheumatology Department, Mater Public Hospital, Dublin 7, Ireland, ⁵UCD Clinical Research Centre, Dublin, Ireland, ⁶Rheumatology, Mater Misericordiae University Hospital, Dublin, Ireland, ⁷Rheumatology, Galway University Hospitals, Galway, Ireland, ⁸Molecular and Cellular Therapeutics, RCSI, Dublin 2, Ireland, ⁹Div of Rheumatology, Mater Misericordiae University Hospital, Dublin, Ireland
Background/Purpose: Patients with gout have an increased risk of cardiovascular events. The presence of tophi is associated with enhanced cardiovascular risk. Increased platelet reactivity is…
Abstract Number: 3128 • 2016 ACR/ARHP Annual Meeting
A Longitudinal Dual Energy Computed Tomography Study on the Effect of Urate Lowering Therapies on the Reduction of Tophus Burden in Patients with Chronic Gout
Hanna Ellmann¹, Sara Bayat¹, Isabelle Oliveira¹, Matthias Englbrecht^2,3, Elizabeth Araujo⁴, Alexander Cavallaro⁵, Silvana Mendonca⁶, Michael Lell⁵, Bernhard Manger², Georg Schett⁷ and Juergen Rech⁷, ¹Medical Department 3, Rheumatology & Clinical Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany, ²Department of Internal Medicine 3, Rheumatology & Clinical Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany, ³Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, ⁴Medical Department 3; Rheumatology & Clinical Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany, ⁵Department of Radiology, University of Erlangen-Nuremberg, Department of Radiology, Erlangen, Germany, ⁶Americas Medical City, Rio de Janeiro, Brazil, ⁷Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany
Background/Purpose: Dual energy computed tomography (DECT) allows reliably detecting and quantifying tophus burden in patients with chronic gout. Longitudinal studies on the effect of uric…
Abstract Number: 3168 • 2015 ACR/ARHP Annual Meeting
How Strong Cardiovascular Risk Factor Are Gouty Tophi?
Rada Gancheva¹, Atanas Kundurdjiev², Mariana Ivanova¹, Todor Kundurzhiev³ and Zlatimir Kolarov⁴, ¹University Hospital "St. Iv. Rilski", Clinic of Rheumatology, Sofia, Bulgaria, ²University Hospital "Alexandrovska", Clinic of Nephrology, Sofia, Bulgaria, ³Medical University, Faculty of Public Health, Sofia, Bulgaria, ⁴Clinic of Rheumatology, University Hospital "St. Iv. Rilski", Clinic of Rheumatology, Sofia, Bulgaria
Background/Purpose: We have not found a study determining cardiovascular (CV) risk in the different stages of gout. This led us to use a complex multimodal…
Abstract Number: 182 • 2014 ACR/ARHP Annual Meeting
Effect of Urate-Lowering Therapy on Radiographic Changes in Gout Patients
Seulkee Lee¹, Inyoung Kim¹, Hyemin Jeong¹, Jiwon Hwang¹, Hyungjin Kim¹, Jaejoon Lee², Hoon-Suk Cha¹ and Eun-mi Koh², ¹Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ²Division of Rheumatology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
Background/Purpose The aim of this study was to investigate the radiographic changes in patients with gout in association with the control of serum uric acid…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].